Innovation Pharmaceuticals announces dose escalation

Innovation has received agreement from the study’s DEC to progress dosing to the second cohort in its Phase 1 trial to investigate the use of delayed release tablets for colonic delivery of Brilacidin in healthy volunteers (Image: Frauke Feind from Pixabay)